High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Clinical trial NCT06971406 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06971406
- Sponsor
- Qiming Wang
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-15
- Primary completion
- 2027-01-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.